Medigen Biotechnology has filed a patent for novel monoclonal antibodies that bind to the SARS-CoV-2 virus or ACE2 receptors. The patent also includes a pharmaceutical composition and a detection kit for SARS-CoV-2. Methods for detection, prevention, and treatment of SARS-CoV-2 or ACE2-mediated diseases are also disclosed. GlobalData’s report on Medigen Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Medigen Biotechnology, Peptide pharmacophores was a key innovation area identified from patents. Medigen Biotechnology's grant share as of September 2023 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
The patent filed is for monoclonal antibodies against sars-cov-2
A recently filed patent (Publication Number: US20230279079A1) describes an isolated antibody against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or its antigen-binding fragment. The antibody consists of a heavy chain variable region (VH) and a light chain variable region (VL). The VH region includes three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), while the VL region includes three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3). The amino acid sequences of these regions are specified in the patent claims.
The patent also covers a pharmaceutical composition comprising the isolated antibody or its antigen-binding fragment, along with a pharmaceutically acceptable carrier. This composition can be used for the detection and treatment of SARS-CoV-2.
Furthermore, the patent describes a kit for detecting the presence of SARS-CoV-2 in a sample. The kit includes the isolated antibody or its antigen-binding fragment, which may be labeled with a detectable label such as an enzymatic, fluorescent, metal, or radio label. The kit can be used in various immunoassay formats, including ELISA, RIA, FIA, LIA, and ILMA.
The patent also discloses a method for detecting SARS-CoV-2 in a sample suspected of containing the virus. The method involves contacting the sample with the isolated antibody or its antigen-binding fragment and assessing the binding of the antibody to the sample. The sample can be urine, stool, or taken from the respiratory tract, such as a nasopharyngeal or nasal swab. The detection can be performed using a sandwich immunoassay or lateral flow assay.
Additionally, the patent claims a method for preventing or treating diseases mediated by angiotensin-converting enzyme 2 (ACE2) in a subject. This method involves administering an effective amount of the isolated antibody or its antigen-binding fragment. One example of such a disease is severe acute respiratory syndrome coronavirus 2 infection.
Finally, the patent covers a nucleic acid sequence encoding the VH, VL, or both regions of the isolated antibody, as well as an isolated host cell containing this nucleic acid.
In summary, this patent describes an isolated antibody against SARS-CoV-2 and its potential applications in detection, prevention, and treatment of the virus. The patent also includes details on the composition, kit, and methods related to the antibody.
To know more about GlobalData’s detailed insights on Medigen Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
